The Infectious Disease Society of American is recommending against the routine use of COVID-19 convalescent plasma.
In February, they were strongly recommending against convalescent plasma for hospitalized immunocompetent covid patients, and weakly advising against it for hospitalized immunocompromised patients. At that point, they were advising its use, weakly, for nonhospitalized high-risk patients with no other treatment options. This strengthens the recommendation against convalescent plasma for immunocompromised patients.
In February, they were strongly recommending against convalescent plasma for hospitalized immunocompetent covid patients, and weakly advising against it for hospitalized immunocompromised patients. At that point, they were advising its use, weakly, for nonhospitalized high-risk patients with no other treatment options. This strengthens the recommendation against convalescent plasma for immunocompromised patients.
From:
no subject
From:
no subject
Oh interesting. I didn't realize adverse transfusion events were so common, but on further thought it makes sense.